Abstract A substantial portion of schizophrenia patients with obsessive compulsive disorder fail to respond to regimen of antipsychotic and selective serotonin reuptake inhibitor. Herein, we report a schizophrenic patient who, after being switched from escitalopram to milnacipran, showed a rapid improvement of his debilitating OCD.
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Abstract Objective: Despite the efficacy of SSRIs and clomipramine, 40%-60% of patients with obsessive-compulsive disorder do not respond adequately to the first line of treatment. This was the case of our patient, a 34-year old female, who demonstrated pronounced magical thinking and an obsessive fear that something terrible would happen to family members. She sought to reduce the impact of these thoughts with mental and motor compulsions (counting, repeating thoughts, bringing things into order and symmetry). Obsessive thoughts and compulsions took up several hours a day, making her exhausted, depressed and inefficient. Aims: As the previous treatment with an SSRI (paroxetine) after 3 months at the maximum tolerated dose (40mg/day) gave only a partial therapeutic response, we augmented the treatment with aripriprazole at a dose of 5mg/day. Review of the literature indicates that adding aripiprazole to an SSRIs could be a valid strategy for treatment-resistant OCD patients or those with only a partial therapeutic response. Aripiprazole is associated with a lower risk of weight gain, sedation, and increase in prolactin compared to other antipsychotics. Method: The following instruments were applied before and two weeks after aripriprazole augmentation: The Beck Anxiety Inventory (BAI), the Beck Depression Inventory-II (BDI-II) and the Obsessive-Compulsive Inventory-Revised (OCI-R). We also followed patients for possible side-effects. Results: Scores on the applied instruments were as follows: before the augmentation with aripriprazole: BAI=10; BDI-II=28, OCI-R= 21; after augmentation with aripriprazole: BAI =3, BDI-II =10, OCI-R=8. Conclusions: Aripriprazole augmentation in a dose of 5mg/day was effective in reduction of obsessive-compulsive symptoms in a patient with partial therapeutic response to paroxetine, as well as in generalized anxiety and depression, with rapid onset of improvement (after 2 weeks of initiation) and good tolerability.
